ATC Group: N05BA11 Prazepam

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05BA11 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05B Anxiolytics
4 N05BA Benzodiazepine derivatives
5 N05BA11 Prazepam

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg

Active ingredients in N05BA11

Active Ingredient Description
Prazepam

Prazepam is a benzodiazepine derivative and has depressant effects on the central nervous system. Benzodiazepines act at the level of the limbic, thalamic, and hypothalamic regions of the CNS and can produce any level of CNS depression required including sedation, hypnosis, skeletal muscle relaxation, and anticonvulsant activity.

Related product monographs

Title Information Source Document Type  
CENTRAX Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
DEMETRIN Tablet Health Products Regulatory Authority (ZA) MPI, Generic

Medicines in this ATC group

France (FR)

Germany (DE)

Ireland (IE)

Netherlands (NL)

South Africa (ZA)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.